Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;24(5):455-461.
doi: 10.1016/j.jmoldx.2022.02.001. Epub 2022 Feb 24.

A Comparison of Seegene Technologies Novaplex SARS-CoV-2 Variants I, II, and IV Assays with Spike Gene Sequencing for Detection of Known Severe Acute Respiratory Syndrome Coronavirus 2 Variants

Affiliations

A Comparison of Seegene Technologies Novaplex SARS-CoV-2 Variants I, II, and IV Assays with Spike Gene Sequencing for Detection of Known Severe Acute Respiratory Syndrome Coronavirus 2 Variants

Marisa C Nielsen et al. J Mol Diagn. 2022 May.

Abstract

Tracking new and emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has become increasingly important for public health responses, primarily because of variant-dependent transmission, disease severity, and treatment decisions. This evaluation compared Seegene Technologies Novaplex SARS-CoV-2 Variants I, II, and IV (I,II&IV) assays to detect known SARS-CoV-2 variants using traditional spike gene Sanger sequencing results as the gold standard reference. Both RNA extraction and extraction-free protocols were assessed. A total of 156 samples were included in this study. There was 100% (109/109) overall agreement (95% CI, 96.7%-100%) between the spike gene sequencing and the I,II&IV results using extracted RNA for the variants included in the Novaplex assay menus. The RNA extraction-free method was 91.7% (143/156) as sensitive (95% CI, 86.2%-95.5%) as the traditional RNA extraction method. Using the extraction-free method on samples with higher cycle threshold values (>30) resulted in some mutations not being detected, presumably due to lower nucleic acid concentrations in the original samples. In conclusion, the I,II&IV assays provide an accurate, rapid, and less labor-intensive method for detecting SARS-CoV-2 and identifying known variants of interest and concern. The RNA extraction-free method for samples with cycle threshold of <30 could be cost-effective for surveillance purposes. However, spike gene sequencing retains the advantage of detecting more and new variants.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Box plots showing CT values in the samples with and without SARS-CoV-2 S gene sequencing results using the RNA extraction method (A) and CT values in the samples with and without results by variants I, II, and IV assays using the extraction-free method (B). The box plots show medians (middle line) and third and first quartiles (boxes), whereas the whiskers show maximum and minimum ranges above and below. The numbers of samples (n) are shown underneath. P values were determined with unpaired, two-sided U-test. ∗∗∗∗P ≤ 0.0001.

Similar articles

Cited by

References

    1. Boehm E., Kronig I., Neher R.A., Eckerle I., Vetter P., Kaiser L. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27:1109–1117. - PMC - PubMed
    1. Castonguay N., Zhang W., Langlois M.-A. Meta-analysis and structural dynamics of the emergence of genetic variants of SARS-CoV-2. Front Microbiol. 2021;12:676314. - PMC - PubMed
    1. Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Peacock S.J., Robertson D.L. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–424. - PMC - PubMed
    1. Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F., Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T., Morgan O., le Polain de Waroux O. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance. 2021;26:2100509. - PMC - PubMed
    1. Davies N., Abbott S., Barnard R., Jarvis C., Kucharski A., Munday J., Pearson C., Russell T., Tully D., Washburne A., Wenseleers T., Gimma A., Waites W., Wong K., van Zandvoort K., Silverman J., Diaz-Ordaz K., Keogh R., Eggo R., Funk S., Jit M., Atkins K., Edmunds W. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. - PMC - PubMed

Publication types

Supplementary concepts